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ABSTRACT: Recently, a number of inhibitors of the enzyme ox-
idosqualene cyclase (OSC; EC 5.4.99.7), a key enzyme in sterol
biosynthesis, were shown to inhibit in mammalian cells the mul-
tiplication of Trypanosoma cruzi, the parasite agent of Chagas’
disease. The gene coding for the OSC of T. cruzi has been cloned
and expressed in Saccharomyces cerevisiae. The expression in
yeast cells could be a safe and easy model for studying the activ-
ity and the selectivity of the potential inhibitors of T. cruzi OSC.
Using a homogenate of S. cerevisiae cells expressing T. cruzi
OSC, we have tested 19 inhibitors: aza, methylidene, vinyl sul-
fide, and conjugated vinyl sulfide derivatives of oxidosqualene
and squalene, selected as representative of different classes of
substrate analog inhibitors of OSC. The IC50 values of inhibition
(the compound concentration at which the enzyme is inhibited
by 50%) are compared with the values obtained using OSC of pig
liver and S. cerevisiae. Many inhibitors of pig liver and S. cere-
visiae OSC show comparable IC50 for T. cruzi OSC, but some
phenylthiovinyl derivatives are 10–100 times more effective on
the T. cruzi enzyme than on the pig or S. cerevisiae enzymes. The
expression of proteins of pathogenic organisms in yeast seems
very promising for preliminary screening of compounds that have
potential therapeutic activity.
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Sterols are eukaryotic membrane components that are neces-
sary to support cell growth and differentiation. Sterol biosyn-
thesis is a well-established chemotherapeutic target in patho-
genic eukaryotes, such as fungi (1,2). The final product of the
sterol biosynthetic pathway in fungi is the 24-alkyl sterol er-
gosterol. Ergosterol or similar 24-alkyl sterols are also the final
products of the sterol synthetic pathway of some pathogenic
protozoa including Trypanosoma species. These organisms
cannot completely substitute these sterols with the cholesterol
biosynthesized in host mammalian cells and need to synthesize
at least some of their own distinctive sterols (3–5). This depen-
dence on sterols suggests that sterol biosynthesis inhibitors
may be useful antiprotozoal drugs.
The sterol biosynthetic pathway (Fig. 1) offers many poten-
tial targets for therapeutic purposes. Many effective antifungal
drugs already in use act by inhibiting different enzymes of
sterol biosynthesis; the allylamine antifungal drug terbinafine
inhibits squalene epoxidase (6), and azole drugs such as keto-
conazole and itraconazole are inhibitors of lanosterol C14-
demethylase (7). The activity of these inhibitors can be ex-
plained as a consequence either of depletion of the ergosterol
or of accumulation of toxic intermediates or side products. In
addition to the antifungal activity, some of these compounds
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FIG. 1. Schematic representation of sterol biosynthetic pathways. The
end products (ergosterol and cholesterol) are typical for fungi and ani-
mals, respectively. In the boxes are shown the enzymes cited in the text
as targets for antimicrobial drugs.
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were shown to inhibit the growth of Trypanosoma and other
kinetoplastid parasites (8). Kinetoplastid parasites have also
been shown recently to be susceptible to inhibitors of squalene
synthase (9,10) and oxidosqualene cyclase (11,12).
The enzyme oxidosqualene cyclase (OSC; EC 5.4.99.7),
which catalyzes the formation of the first cyclic precursor of
sterols, is considered a good target for the inhibition of sterol
biosynthesis in both humans and fungi. Many inhibitors, de-
signed on the basis of the complex cyclization mechanism of
OSC (13), are active on the enzyme and have been investigated
as potential cholesterol-lowering or antifungal drugs (1,2,13).
The recent crystallization of human OSC as a complex with the
potent inhibitor RO48–8071 opens the way to new structure-
based studies of the cyclization mechanism (14).
We have designed and tested against mammalian and fun-
gal OSC many acyclic substrate analogs modified either to
mimic the high-energy carbocationic intermediates (com-
pounds 1–3 of Fig. 2) or to bear reactive functions able to in-
teract with the active site residues, as the methylidene (com-
pounds 4–8), vinyl sulfide (compounds 9, 12, 13, 16), conju-
gated vinyl sulfide (compounds 10, 11, 14, 15, 17),
hydroxysulfide (compound 19), or hydroxyphenyl derivatives
(compound 18) (15–20). OSC of different origins can have sig-
nificantly different susceptibilities to the inhibitors, showing
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FIG. 2. Squalene and 2,3-oxidosqualene derivatives tested as inhibitors of Trypanosoma cruzi
oxidosqualene cyclase.
the possibility of selective inhibition (19,20). Therefore, it
would be worth testing the activity of these inhibitors on the
OSC of the pathogen protozoon Trypanosoma cruzi, which re-
cently has been shown to be susceptible to pyridinium ion-
based inhibitors and to some umbelliferone aminoalkyl deriva-
tives (11,12). Trypanosoma cruzi, like other pathogenic proto-
zoa, is difficult to culture for an extensive, preliminary
screening of the many available, effective inhibitors of OSC.
Recently, the gene coding for the OSC of T. cruzi, a lanosterol
synthase, has been cloned and expressed in Saccharomyces
cerevisiae (21). The enzyme expressed in the yeast cells could
be a safe and easy model for a preliminary study of the activity
and the selectivity of the potential inhibitors of T. cruzi OSC.
In this paper we report the activity of different types of sub-
strate analogs as inhibitors of the T. cruzi OSC expressed in S.
cerevisiae cells. Basically, three types of inhibitors were stud-
ied: analogs of the carbocationic intermediates, as the aza-
squalenes (15,18); oxidosqualene derivatives bearing a conju-
gated methylidene group, designed as affinity-labeling in-
hibitors (16,22); and vinyl sulfide, and conjugated vinyl sulfide
derivatives of oxidosqualene, very effective inhibitors of yeast
OSC (17,19,20), (Fig. 2).
MATERIALS AND METHODS
Materials, substrates, and test compounds. All the components
of buffers and culture broths were obtained from Sigma-
Aldrich (Milan, Italy) unless otherwise specified.
The substrate of OSC, 2,3-oxidosqualene, was synthesized
as previously described (23). The labeled [14C]-(3S)2,3-oxi-
dosqualene was obtained through biological synthesis by incu-
bating a pig liver S10 supernatant with R,S[2-14C]mevalonic
acid (55 mCi/mmol, 2.04 GBq/mmol) (Amersham Pharmacia
Biotech, Buckinghamshire, United Kingdom), in the presence
of the OSC inhibitor U-14266A (24), as previously described
(19). [2-14C]Acetate (50 mCi/mol) was obtained from Amer-
sham Pharmacia Biotech. The synthesis of the inhibitors tested
(compounds 1–19 of Fig. 2) has been described elsewhere
(16,17,19,20,23,25,26). The identity and purity of inhibitors
was checked by TLC, 1H NMR and mass spectra before test-
ing the inhibition of T. cruzi OSC.
Strains of S. cerevisiae and culture conditions. SMY8pBJ1.21
strain, expressing the OSC of T. cruzi; SMY8pSM61.21, ex-
pressing the wild-type yeast OSC; and SMY8pSM60.21, ex-
pressing the Arabidopsis thaliana OSC obtained by transforma-
tion of lanosterol synthase mutant strain of S. cerevisiae SMY8
(MATα erg7::HIS3 hem1::TRP1 ura3–52-trpl-∆63 leu2–3.112
his3-∆200 ade2 Gal+) were kindly provided by Professor S.P.T.
Matsuda [Department of Chemistry and Biochemistry and Cell
Biology, Rice University, Houston, TX (21,27,28)]. All strains
were grown in a YPD culture broth (yeast extract 1%, peptone
2%, dextrose 2%) containing hemin (0.013 mg/mL) and ergos-
terol (0.02 mg/mL). Hemin had to be added to the growth
medium since the SMY8 strains contains a mutation
(hem1::TRP1) affecting heme biosynthesis. The presence of a
heme mutant background is necessary for the viability of lanos-
terol synthase mutants in aerobic conditions (27). OSC expres-
sion was induced in YPG broth (yeast extract 1%, peptone 2%,
galactose 2%) containing hemin (0.013 mg/mL). All strains were
preserved in 40% glycerol at –80°C.
Enzymatic assays. The activity of OSC was assayed in cell-
free homogenates obtained from cultures grown to late expo-
nential phase in YPG at 30°C. The cells were centrifuged at
3000 × g for 10 min and the homogenates prepared by lysing
the cell wall with lyticase (2 mg/g wet cells in 1.2 M sorbitol,
0.02 M KH2PO4, pH 7.4, for 60 min at 30°C). The spheroplasts
obtained after lysis were sedimented at 3000 × g for 10 min,
washed twice with 1.2 M sorbitol, 0.02 M KH2PO4 and ho-
mogenized with a Potter device in 10 mM MES/TRIS buffer,
containing 0.2 mM EDTA and 1 mM PMSF, pH 6.9. Proteins
in the homogenate were quantified with the Protein Assay Kit
SIGMA, based on the method of Lowry, modified by Peterson
(29). The homogenates could be used fresh or after storage at
–80°C for several months. The OSC activity was assayed by
incubating the homogenate in the presence of the labeled [14C]-
(3S)-2,3-oxidosqualene (1000 cpm) diluted with unlabeled
(R,S)2,3-oxidosqualene to a final concentration of 25 µM. Cold
and labeled substrates and inhibitors, when present, were added
as solutions in CHCl3 to test tubes in the presence of Tween-80
(0.2 mg/mL of final volume) and Triton X-100 (1 mg/mL of
final volume). The solvent was evaporated under nitrogen. The
substrate and inhibitors were dissolved in 50 µL of MES/TRIS
buffer, containing 0.2 mM EDTA, pH 6.9 and the amount of
homogenate necessary to obtain a 20% substrate transforma-
tion was added and diluted to a final volume of 250 µL buffer.
After 30 min of incubation at 35°C in plugged tubes, the enzy-
matic reaction was stopped by adding 1 mL of KOH in
methanol (10% wt/vol) and heating at 80°C for 30 min in a
water bath. After extracting with 2 mL of petroleum ether, the
solvent was evaporated and the extract was dissolved in a small
amount of CH2Cl2 and spotted on TLC plates (Alufolien
Kieselgel 60F254; Merck, Darmstadt, Germany) using n-hex-
ane/ethyl acetate (85:15, vol/vol) as developing solvent. The
conversion of the labeled substrate into labeled lanosterol was
analyzed by a System 200 Imaging Scanner (Hewlett-Packard,
Palo Alto, CA); the counts were collected for 5 min, and the
percentage of transformation was calculated by integration. For
the Km determinations different final concentrations of sub-
strate (1–200 µM) were used and the incubation times arranged
to obtain percentages of transformation not exceeding 10% (to
keep safely within the range of linear relationship between
product formation and time of reaction). The values of the en-
zymatic rate obtained at the different substrate concentrations
were fitted by a nonlinear regression method to the Michaelis–
Menten equation to calculate the Km (30).
IC50 values (the concentration of inhibitor that reduces the
enzymatic conversion by 50%) were calculated by nonlinear
regression analysis of the residual activity vs. the log of con-
centrations of inhibitors. The values in the table are the means
of two separate experiments each in duplicate.
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RESULTS
Inhibition of T. cruzi OSC in cell-free homogenate of
SMY8pBJ1.21 strain. To screen the inhibitors we used a ho-
mogenate of cells of the SMY8pBJ1.21 strain grown to late ex-
ponential phase. The T. cruzi OSC, known to partition between
the cytosolic lipid bodies and the microsomes (31), was highly
expressed in these cells. Detergents are needed to ensure the
access of the apolar substrate and inhibitors to the enzyme in
the lipid bodies and in the membranes and were used accord-
ing to previous experiences (15,16,32). The enzyme activity
was evaluated by radiometric scanning of thin-layer chromato-
grams of the organic extract of incubation mixtures. In our ex-
perimental conditions (plugged test tubes with no NADPH
added), the only labeled peaks detected corresponded to cold
standards of 2,3-oxidosqualene and lanosterol. No label was
found in the 4-desmethylsterol region.
The specific activity, expressed as nmol of lanosterol
formed, was 4 nmol/h/mg of proteins. The value of Km, calcu-
lated by a nonlinear regression method, was 66 ± 13.5 µM.
To check the reliability and suitability of this homogenate
for inhibition studies, we determined that the Km values of the
S. cerevisiae and A. thaliana enzymes expressed in the same
host were, respectively, 30 ± 14.2 and 91 ± 29.6 µM, in agree-
ment with the data reported for these enzymes using different
enzymatic preparations (33,34). Therefore, the OSC expressed
in transformed SMY8 cells have the same affinity for the sub-
strate previously determined and seem suitable for testing in-
hibitors and comparing the results with those previously ob-
tained with OSC of different origin.
All the inhibitors assayed, illustrated in Figure 2 and listed in
Table 1, are substrate analogs already tested on mammalian and
fungal OSC and were chosen as the more representative of dif-
ferent classes of compounds designed to inhibit OSC by differ-
ent mechanisms. Prior to testing the inhibition of T. cruzi OSC,
compound 1 was tested with the S. cerevisiae OSC expressed in
yeast, compounds 12 and 16 were tested with pig liver enzyme.
The IC50 values determined and found to be the same as those
reported in References 18 and 20, respectively.
Table 1 shows the IC50 values obtained with some aza and
methylidene derivatives of the substrate and with a series of
vinyl and conjugated sulfide derivatives of truncated oxi-
dosqualene. The activities are compared with those obtained
previously by using detergent-solubilized microsomes pre-
pared from pig liver and S. cerevisiae cells. The azasqualene
derivatives are the 2-aza-2,3-dihydrosqualene 1, its N-oxide 2,
and the 19-azasqualene 3 (25,26). The OSC of T. cruzi and of
pig liver are inhibited similarly by 2-aza derivatives 1 and 2,
but not by 19-aza derivative 3, which is a 30 times less effec-
tive inhibitor of T. cruzi enzyme. The methylidene derivatives
4, 6, 7, and 8 show comparable activities against the T. cruzi
and pig liver enzyme whereas compound 5 is five times less ef-
fective on T. cruzi OSC. As already observed for mammalian
enzyme, the isomers of inhibitor with the same configuration
as the substrate are at least 10 times more effective (16). The
presence of a vinyl function in position 2 as in the trans 2-
vinyl-2-oxido-1,1-bisnorsqualene 8, as already observed in pig
and S. cerevisiae OSC, is not effective for inhibition (18).
Compounds 9–19 of Table 1 are vinyl and conjugated sul-
fide derivatives of truncated oxidosqualene (17,19,20). The T.
cruzi OSC seems specifically inhibited by all the phenyl deriv-
atives tested, i.e., compounds 12, 16, 17, 18, and 19. The IC50
values for these derivatives are in the range 70–600 nM, or 10
to 100 times lower than the IC50 found in pig liver OSC. Fur-
thermore, the corresponding methyl derivatives 9, 13, 14, and
15, which are very active in pig and S. cerevisiae (19,20), are
less effective on T. cruzi OSC. The major difference is observed
with compound 9, showing, with T.cruzi, a 30 times larger IC50
than with S. cerevisiae. Compounds 13 and 16 were also tested
with the OSC of A. thaliana, expressed in the yeast strain
SMY8pSM60.21. The IC50 of both compounds were similar,
4.5 and 2 µM, respectively. IC50 of phenyl derivatives 12, 16,
17 and 19, tested with the OSC of S. cerevisiae expressed in a
SMY8-derived strain (SMY8pSM61.21) were in complete ac-
cordance with the data shown in Table 1, obtained previously
(18,20) with a wild-type S. cerevisiae (33).
DISCUSSION
We used a mutant strain of S. cerevisiae expressing the OSC of
the pathogen protozoon T. cruzi to test a series of OSC in-
hibitors, with the aim of determining the susceptibility of this
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TABLE 1
Inhibition of Trypanosoma cruzi OSC Expressed in SMY8pBJ1.21 Yeast
Strain by Aza, Methylidene, and Vinyl and Dienic Sulfide Derivatives
of Substrate Compared with IC50 Previously Obtained with OSC from




Compounda T. cruzi Pig liverc S. cerevisiaec
1 0.8 0.15 10.0
2 4.0 3.3 16.0
3 50.0 1.7 35.0
4 5.5 3.5 1.5
5 100.0 20.0 15.0
6 2.0 4.0 5.0
7 0.2 0.4 1.0
8 100.0 100.0 50.0
9 1.7 1.0 0.05
10 >100 1.2 0.4
11 >100 1.0 0.9
12 0.09 7.0 1.0
13 18.0 5.0 1.5
14 12.0 3.6 6.0
15 10.0 2.6 2.0
16 0.07 7.0 10.0
17 0.6 20.0 12.0
18 0.15 9.0 >100
19 0.5 7.5 40.0
aFor structures of these compounds see Figure 2.
bValues are the means of two separate experiments, each with duplicate in-
cubations. The maximal deviations from the mean were less than 10%.
cSee References 16–20. OSC, oxidosqualene cyclase; IC50, inhibitor con-
centration reducing enzymatic activity by 50%.
enzyme to different types of OSC inhibitors and possibly iden-
tifying specific inhibitors. OSC can be considered a promising
target to inhibit the multiplication of pathogenic microbes, but,
unlike some targets for sterol inhibition, such as ∆24 methyl
transferase, OSC also is present in the mammalian cells. Speci-
ficity for the pathogen enzyme is consequently an important
prerequisite for inhibitors.
We have tested 19 inhibitors, selected as representative of
different classes of inhibitors. The azasqualene derivatives,
which were designed as analogs of the high-energy carboca-
tionic intermediates generated at C-2 after the opening of the
oxiranic ring, or at C-19, after the closure of the fourth ring,
have been well studied as inhibitors of mammalian and fungal
OSC (15,25,26). From the comparison of the IC50 obtained
with the T. cruzi and with the pig and S. cerevisiae OSC, these
compounds do not show specificity for the T. cruzi enzyme,
probably because the mechanism of the initial step of the cy-
clization is very conserved in all the OSC (13). The closure of
the last ring and the rearrangement are probably differently
controlled in different OSC, as the 19-aza-derivative is very ac-
tive only against pig liver OSC. The 29-methylidene deriva-
tives 4–7, previously shown to be time-dependent inhibitors
(16,22), similarly lack specificity.
The most selective inhibition of T. cruzi OSC was found in
the series of vinyl-thio-derivatives. The design of these com-
pounds was based on the hypothesis that a partial cyclization of
these compounds in the active site of the enzyme, because of the
excellent properties of the sulfur in stabilizing the electron-defi-
cient α-carbon, owing to its good pi- and σ-donor properties,
could generate carbocationic intermediates that were more sta-
ble and more able to interact strongly with nucleophilic amino
acid residues. Our previous results showed that a methyl sulfide
derivative, such as compound 9, is a very effective inhibitor of S.
cerevisiae OSC and a time-dependent inhibitor of pig OSC,
whereas phenyl sulfide derivatives, such as 16, 17, and 19, are
poor inhibitors of both pig and yeast OSC (17,19,20). The T.
cruzi OSC seems to be specifically inhibited by all the phenyl
derivatives tested (compounds 12, 16–19). On the basis of these
results, we initially speculated that the inhibition could be as-
cribed to specific pi-pi interaction of the aromatic derivatives with
the Tyr540 of T. cruzi (21), which in the other lanosterol syn-
thases is substituted for a conserved threonine residue. A tyro-
sine is conserved at this position in cycloartenol synthase
(35,36), the plant enzyme converting oxidosqualene into cy-
cloartenol, the precursor of plant sterols. The type of amino acid
present in this position seems catalytically relevant for determin-
ing the final product of cyclization. Mutagenesis experiments
have shown that the T/Y substitution causes a loss of accuracy
in determining the final product of cyclization. A S. cerevisiae
T384Y mutant produces substantial amounts of parkeol and
lanost-24-ene-3β,9α-diol in addition to lanosterol (35), and the
Y410T mutant of A. thaliana does not form cycloartenol, but
rather lanosterol and 9β-lanosta-7,24-dien-3β-ol (36). To test the
hypothesis that Tyr540 determines inhibitor specificity, we stud-
ied the inhibition of compounds 13 and 16 using a homogenate
of a SMY8pSM60.21 strain expressing the OSC of A. thaliana.
In contrast to our hypothesis, both the methyl and the phenyl de-
rivatives showed similar IC50, respectively, 4.5 and 2 µM. There-
fore, the specificity of the aromatic derivatives for the T. cruzi
OSC may result from more complex differences between the two
active sites, allowing different interactions with the inhibitors
and possibly relating to the mechanism of control of the re-
arrangement and of the formation of the final product (37).
In conclusion, our results show that the homogenate of a
yeast strain expressing enzymes of pathogenic organisms can
be used for a preliminary screening of compounds potentially
active against eukaryotic pathogenic organisms in totally safe
conditions. The aromatic vinyl-thio-derivatives of the substrate
of OSC are very promising candidates for the inhibition of
sterol biosynthesis in T. cruzi and possibly related pathogens,
and could also be considered as models for the design of new
inhibitors.
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